VBIO
Valion Bio, Inc.
Healthcare — Biotechnology
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Price History
Fundamentals
| Market Cap | $1.59M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-6.66 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -182.22% |
| Debt/Equity | 153.99 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 29.5 |
| Beta | 1.80 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.60 |
| 52-Week Low | $0.46 |
| 50-Day Avg | $0.82 |
| 200-Day Avg | $1.50 |
| Avg Volume | 323.8K |
| Volume | 4.0K |
Performance Analysis
BULLISHVBIO shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:36 UTC
Back to Screener Export Report